This segment focuses on the discovery and development of small molecule therapies targeting oncogenic mutations in genetically defined cancers. Research and development activities include identifying and validating novel drug targets, designing and synthesizing small molecule inhibitors, and conducting preclinical and clinical studies. The company utilizes its MAP (MasterKey) discovery engine to identify and develop therapies. Technologies employed include structure-based drug design, medicinal chemistry, and in vitro and in vivo pharmacology. The primary therapeutic area is oncology, with a focus on EGFR and BRAF mutations. The goal is to improve patient outcomes by providing targeted therapies with the potential for higher efficacy and reduced side effects. Market positioning is as a precision oncology company, competing with other companies developing targeted cancer therapies. Future opportunities include expanding the pipeline to address additional cancer types and mutations. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate safety and efficacy. Partnerships with companies like Servier and OpenEye Scientific support drug development and platform expansion.